These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 24640574)

  • 1. Anti-arthritic actions of relaxin, in combination with estrogens, in joint and bone tissue.
    Bagnell CA; Santora K; Ho TY
    Ital J Anat Embryol; 2013; 118(1 Suppl):60-1. PubMed ID: 24640574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG), in rat adjuvant-induced arthritis.
    Ho TY; Santora K; Chen JC; Frankshun AL; Bagnell CA
    Bone; 2011 Jun; 48(6):1346-53. PubMed ID: 21419242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiarthritic effects of relaxin, in combination with estrogen, in rat adjuvant-induced arthritis.
    Santora K; Rasa C; Visco D; Steinetz BG; Bagnell CA
    J Pharmacol Exp Ther; 2007 Aug; 322(2):887-93. PubMed ID: 17526806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of relaxin in a model of rat adjuvant-induced arthritis.
    Santora K; Rasa C; Visco D; Steinetz B; Bagnell C
    Ann N Y Acad Sci; 2005 May; 1041():481-5. PubMed ID: 15956749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
    Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis.
    Redlich K; Görtz B; Hayer S; Zwerina J; Doerr N; Kostenuik P; Bergmeister H; Kollias G; Steiner G; Smolen JS; Schett G
    Am J Pathol; 2004 Feb; 164(2):543-55. PubMed ID: 14742260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis.
    Stolina M; Adamu S; Ominsky M; Dwyer D; Asuncion F; Geng Z; Middleton S; Brown H; Pretorius J; Schett G; Bolon B; Feige U; Zack D; Kostenuik PJ
    J Bone Miner Res; 2005 Oct; 20(10):1756-65. PubMed ID: 16160733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The natural flavonoid galangin inhibits osteoclastic bone destruction and osteoclastogenesis by suppressing NF-κB in collagen-induced arthritis and bone marrow-derived macrophages.
    Huh JE; Jung IT; Choi J; Baek YH; Lee JD; Park DS; Choi DY
    Eur J Pharmacol; 2013 Jan; 698(1-3):57-66. PubMed ID: 22985747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kirenol exerts a potent anti-arthritic effect in collagen-induced arthritis by modifying the T cells balance.
    Lu Y; Xiao J; Wu ZW; Wang ZM; Hu J; Fu HZ; Chen YY; Qian RQ
    Phytomedicine; 2012 Jul; 19(10):882-9. PubMed ID: 22673798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis.
    Chao CC; Chen SJ; Adamopoulos IE; Davis N; Hong K; Vu A; Kwan S; Fayadat-Dilman L; Asio A; Bowman EP
    Autoimmunity; 2011 May; 44(3):243-52. PubMed ID: 20925596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio.
    Seriwatanachai D; Thongchote K; Charoenphandhu N; Pandaranandaka J; Tudpor K; Teerapornpuntakit J; Suthiphongchai T; Krishnamra N
    Bone; 2008 Mar; 42(3):535-46. PubMed ID: 18166509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with anti-gamma-glutamyl transpeptidase antibody attenuates osteolysis in collagen-induced arthritis mice.
    Ishizuka Y; Moriwaki S; Kawahara-Hanaoka M; Uemura Y; Serizawa I; Miyauchi M; Shibata S; Kanaya T; Takata T; Taniguchi N; Niida S
    J Bone Miner Res; 2007 Dec; 22(12):1933-42. PubMed ID: 17680722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis.
    Orosa B; García S; Martínez P; González A; Gómez-Reino JJ; Conde C
    Ann Rheum Dis; 2014 Jan; 73(1):298-305. PubMed ID: 23486415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF-κB activation and down regulating inflammatory cytokines.
    Naidu VG; Dinesh Babu KR; Thwin MM; Satish RL; Kumar PV; Gopalakrishnakone P
    Chem Biol Interact; 2013 Apr; 203(2):467-79. PubMed ID: 23333834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1.
    Koenders MI; Lubberts E; Oppers-Walgreen B; van den Bersselaar L; Helsen MM; Di Padova FE; Boots AM; Gram H; Joosten LA; van den Berg WB
    Am J Pathol; 2005 Jul; 167(1):141-9. PubMed ID: 15972960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.
    Kong YY; Feige U; Sarosi I; Bolon B; Tafuri A; Morony S; Capparelli C; Li J; Elliott R; McCabe S; Wong T; Campagnuolo G; Moran E; Bogoch ER; Van G; Nguyen LT; Ohashi PS; Lacey DL; Fish E; Boyle WJ; Penninger JM
    Nature; 1999 Nov; 402(6759):304-9. PubMed ID: 10580503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.
    Lubberts E; Koenders MI; Oppers-Walgreen B; van den Bersselaar L; Coenen-de Roo CJ; Joosten LA; van den Berg WB
    Arthritis Rheum; 2004 Feb; 50(2):650-9. PubMed ID: 14872510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models.
    Schett G; Middleton S; Bolon B; Stolina M; Brown H; Zhu L; Pretorius J; Zack DJ; Kostenuik P; Feige U
    Arthritis Rheum; 2005 May; 52(5):1604-11. PubMed ID: 15880601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data.
    Bendele A; McAbee T; Sennello G; Frazier J; Chlipala E; McCabe D
    Arthritis Rheum; 1999 Mar; 42(3):498-506. PubMed ID: 10088773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone remodeling in rheumatic disease: a question of balance.
    Walsh NC; Gravallese EM
    Immunol Rev; 2010 Jan; 233(1):301-12. PubMed ID: 20193007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.